Mobile health clinics for distribution of vaccinations to underserved communities during health emergencies: A COVID-19 case study.

Lior Rennert, Fatih Gezer, Iromi Jayawardena, Kerry A Howard, Kevin J Bennett, Alain H Litwin, Kerry K Sease
Author Information
  1. Lior Rennert: Department of Public Health Sciences, Clemson University, Clemson, SC, USA.
  2. Fatih Gezer: Department of Public Health Sciences, Clemson University, Clemson, SC, USA.
  3. Iromi Jayawardena: Department of Public Health Sciences, Clemson University, Clemson, SC, USA.
  4. Kerry A Howard: Department of Public Health Sciences, Clemson University, Clemson, SC, USA.
  5. Kevin J Bennett: University of South Carolina School of Medicine - Columbia, Columbia, SC, USA.
  6. Alain H Litwin: Prisma Health-Upstate, Greenville, SC, USA.
  7. Kerry K Sease: University of South Carolina School of Medicine - Greenville, Greenville, SC, USA.

Abstract

Objectives: Mobile health clinics (MHCs) effectively provide healthcare to underserved communities. However, their application during health emergencies is understudied. We described the implementation of an MHC program delivering vaccinations during the COVID-19 pandemic, examined the program's reach to medically underserved communities, and investigated characteristics of vaccination uptake in order to inform the utility of MHCs during health emergencies.
Study design: The study observed COVID-19 MHC vaccination rates and factors associated with uptake between February 20th, 2021, and February 17th, 2022.
Methods: Prisma Health deployed six MHCs to underserved communities. We described the characteristics of individuals who utilized the MHCs and evaluated census tract-level community factors associated with use of the MHCs through generalized linear mixed effects models.
Results: The MHCs conducted 260 visits at 149 unique sites in South Carolina, providing 12,102 vaccine doses to 8545 individuals: 2890 received a partial dose, 4355 received a primary series, and 1300 received a booster dose. Among individuals utilizing the MHC, the median age was 42 years (IQR: 22-58), 44.0 % were Black, 49.2 % were male, and 44.2 % were uninsured. Black, Hispanic, and uninsured individuals were significantly more likely to utilize MHC services for COVID-19 vaccination. During periods when vaccines were limited, MHC utilization was significantly greater in communities facing access barriers to healthcare.
Conclusions: The high COVID-19 vaccination uptake at MHCs demonstrated that the MHC framework is an effective and acceptable intervention among medically underserved populations during health emergencies, especially when resources are scarce. The identified factors associated with vaccination uptake demonstrated that the MHCs had the greatest impact in higher-risk communities and can be used to inform allocation of such field-level interventions in future health emergencies.

Keywords

References

  1. Open Forum Infect Dis. 2021 Apr 02;8(6):ofab152 [PMID: 34183979]
  2. PLoS One. 2012;7(8):e40984 [PMID: 22927904]
  3. JAMA Health Forum. 2021 Mar 1;2(3):e210434 [PMID: 36218456]
  4. Lancet. 2021 May 22;397(10288):1863-1865 [PMID: 33894143]
  5. Am J Public Health. 2021 Apr;111(4):586-588 [PMID: 33689446]
  6. Sci Adv. 2023 Jan 18;9(3):eabq0199 [PMID: 36652520]
  7. Am J Prev Med. 2020 Sep;59(3):326-332 [PMID: 32703702]
  8. Vaccine. 2014 Jul 31;32(35):4399-4403 [PMID: 24968154]
  9. JAMA Health Forum. 2021 Feb 1;2(2):e210114 [PMID: 36218793]
  10. J Health Monit. 2020 Oct 09;5(Suppl 7):3-17 [PMID: 35146298]
  11. Glob Health Sci Pract. 2015 Mar 05;3(1):109-16 [PMID: 25745124]
  12. Am J Public Health. 2012 Mar;102(3):406-10 [PMID: 22390503]
  13. Lancet. 2021 Jul 10;398(10295):101-103 [PMID: 33991477]
  14. Int J Equity Health. 2020 May 19;19(1):73 [PMID: 32429920]
  15. Lancet Public Health. 2021 Oct;6(10):e720-e728 [PMID: 34118194]
  16. Lancet Reg Health Am. 2023 Dec 14;29:100648 [PMID: 38124995]
  17. Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109143 [PMID: 34794060]
  18. Clin Pediatr (Phila). 2020 Jun;59(7):706-715 [PMID: 32111120]
  19. Vaccine. 2021 Dec 17;39(51):7441-7445 [PMID: 34782160]
  20. BMJ. 2021 Mar 12;372:n485 [PMID: 33712471]
  21. Public Health Nurs. 1998 Feb;15(1):3-11 [PMID: 9503947]
  22. JMIR Public Health Surveill. 2023 Feb 10;9:e41450 [PMID: 36763450]
  23. Matern Child Health J. 2010 Jul;14(4):528-34 [PMID: 19685179]
  24. J Racial Ethn Health Disparities. 2021 Jun;8(3):543-546 [PMID: 33783755]
  25. Vaccines (Basel). 2021 Jun 03;9(6): [PMID: 34204971]
  26. PNAS Nexus. 2022 Sep 30;1(4):pgac207 [PMID: 36714849]
  27. Int J Equity Health. 2022 Jan 14;21(1):6 [PMID: 35031078]
  28. Int J Equity Health. 2020 Mar 20;19(1):40 [PMID: 32197637]
  29. J Behav Med. 2019 Oct;42(5):883-897 [PMID: 30635862]
  30. Glob Health J. 2021 Mar;5(1):51-55 [PMID: 33585053]
  31. J Subst Abuse Treat. 2019 Aug;103:1-8 [PMID: 31229187]
  32. Int J Equity Health. 2017 Oct 5;16(1):178 [PMID: 28982362]
  33. JAMA. 2021 Jan 12;325(2):123-124 [PMID: 33331845]
  34. J Community Health. 2013 Apr;38(2):338-48 [PMID: 23054419]
  35. BMJ. 2021 May 20;373:n1138 [PMID: 34016653]
  36. Vaccines (Basel). 2022 Jan 29;10(2): [PMID: 35214670]
  37. JAMA Health Forum. 2021 Mar 1;2(3):e210264 [PMID: 36218461]
  38. J Aging Soc Policy. 2020 Jul-Oct;32(4-5):396-402 [PMID: 32475255]
  39. Ann Intern Med. 2022 Apr;175(4):505-512 [PMID: 35188790]
  40. Cancer Cytopathol. 2016 Aug;124(8):581-8 [PMID: 27070446]
  41. Health Psychol Behav Med. 2014 Jan 1;2(1):359-378 [PMID: 25750788]
  42. J Rural Health. 2021 Mar;37(2):278-286 [PMID: 33619746]
  43. Sex Transm Dis. 2003 Aug;30(8):654-8 [PMID: 12897689]
  44. Prev Med. 2022 Oct;163:107226 [PMID: 36029925]
  45. J Community Health. 2014 Oct;39(5):922-34 [PMID: 25135842]
  46. Vaccine. 2013 Apr 12;31(16):2028-34 [PMID: 23474310]
  47. J Pediatr Ophthalmol Strabismus. 2015 Mar-Apr;52(2):98-105 [PMID: 25798708]
  48. Health Aff (Millwood). 2021 Mar;40(3):419-425 [PMID: 33539178]
  49. J Public Health Manag Pract. 2010 Jan-Feb;16(1):E1-8 [PMID: 20009632]
  50. Lancet Glob Health. 2021 Jun;9(6):e749-e750 [PMID: 33713634]
  51. J Epidemiol Community Health. 2020 Nov;74(11):964-968 [PMID: 32535550]
  52. Lancet Public Health. 2024 Jun;9(6):e354-e364 [PMID: 38821682]
  53. Lancet. 2017 Dec 9;390(10112):2602-2604 [PMID: 28622953]
  54. Matern Child Health J. 2007 May;11(3):235-9 [PMID: 17243022]
  55. J Community Health. 2014 Jun;39(3):599-605 [PMID: 24343196]
  56. JAMA. 2021 Jun 15;325(23):2397-2399 [PMID: 34028495]

Word Cloud

Created with Highcharts 10.0.0healthMHCscommunitiesunderservedemergenciesMHCCOVID-19vaccinationuptakeMobileclinicsfactorsassociatedindividualsreceivedhealthcaredescribedvaccinationsmedicallycharacteristicsinformstudyFebruaryHealthdose44Black2 %uninsuredsignificantlydemonstratedallocationObjectives:effectivelyprovideHoweverapplicationunderstudiedimplementationprogramdeliveringpandemicexaminedprogram'sreachinvestigatedorderutilityStudydesign:observedCOVID-19 MHCrates20th202117th2022Methods:Prismadeployedsixutilizedevaluatedcensustract-levelcommunityusegeneralizedlinearmixedeffectsmodelsResults:conducted260visits149uniquesitesSouthCarolinaproviding12102vaccinedoses8545individuals:2890partial4355primaryseries1300boosterAmongutilizingmedianage42yearsIQR:22-580 %49maleHispaniclikelyutilizeservicesperiodsvaccineslimitedutilizationgreaterfacingaccessbarriersConclusions:highframeworkeffectiveacceptableinterventionamongpopulationsespeciallyresourcesscarceidentifiedgreatestimpacthigher-riskcanusedfield-levelinterventionsfuturedistributionemergencies:caseResourceUnderservedVaccination

Similar Articles

Cited By